Alzheimer’s Disease Drug Aricept Faces Rising Tide of Generic Competitors

The patent wall protecting Eisai’s blockbuster Alzheimer’s disease drug Aricept is crumbling fast with two more generic companies receiving U.S. Food and Drug Administration approval this week to take on the drug that Eisai manufactures at its Research Triangle Park, North Carolina, facility.
Med City News